The latest peptide research, lab-quality, and regulatory news — summarized in plain language and linked to primary sources. For informational use only; not medical advice. 21+.
-
How Peptides Are Analysed: HPLC, LC–MS/MS and Stability Testing
A 2026 review in Separation Science Plus surveys peptide analysis methods and names LC–MS/MS the gold standard for quantification. How chromatographic purity, mass-spectrometric identity and stability testing answer different questions.
-
Boehringer Ingelheim’s Triple Receptor Agonist BI 3034701 Enters Phase II
Boehringer Ingelheim says its investigational GLP-1/GIP/NPY2 triple receptor agonist BI 3034701 has entered Phase II development for obesity. What the company announced, and what a Phase II start does and does not mean.
-
Pharmacopeias move toward recombinant Factor C for endotoxin testing
USP and the European Pharmacopoeia now formally recognise recombinant Factor C for bacterial endotoxin testing, and why endotoxin is a separate result on a COA.
-
CagriSema is under FDA review, with a decision anticipated by late 2026
Novo Nordisk filed CagriSema with the FDA in December 2025 and says a decision is anticipated by late 2026. What the REDEFINE trials showed, and what REDEFINE 4 did not.
-
Peptide Science and Evidence: Inside a Nature Feature
A June 2026 Nature feature weighs the science behind the peptide craze, contrasting roughly 100 approved peptide drugs with under-studied “research use only” compounds.
-
Second PCAC Peptides Meeting Expected by Early 2027
The FDA’s compounding advisory committee is expected to weigh five more peptides — LL-37, GHK-Cu, Dihexa, Melanotan II and PEG-MGF — for the 503A list by early 2027.
-
Retatrutide Meets Endpoints in Two More Phase 3 Trials
Lilly reported that investigational retatrutide met endpoints in the TRIUMPH-2 and TRIUMPH-3 Phase 3 trials, with a BLA submission planned for Q1 2027.
-
503A vs 503B Compounding: Two Pathways, and Where GLP-1s Stand
503A and 503B are two distinct legal compounding pathways under the FD&C Act. Here is how they differ and where research peptides and GLP-1s currently stand.
-
FDA Publishes 17 Revised Draft Guidances for Generic Peptide Products
The FDA published 17 revised draft product-specific guidances for generic peptide products on July 28, 2026, updating impurity, endotoxin and structure recommendations.
-
FDA Advisory Panel Recommends Six of Seven Peptides for 503A Compounding
An FDA advisory committee recommended six of seven peptides, including BPC-157 and TB-500, for the 503A compounding bulks list at its July 2026 meeting.
-
Research Note: Review Surveys AI-Driven Antimicrobial Peptide Discovery
A review in Frontiers in Bioinformatics surveys how big data, modeling and AI are advancing computational antimicrobial peptide (AMP) discovery — a methods-focused look at the research.
-
FDA Staff Recommend Against Adding Seven Peptides to the 503A Compounding List
FDA briefing documents recommend against adding BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon to the 503A compounding list before the July 23–24 PCAC meeting.
-
Retatrutide’s Phase 3 diabetes data published in The Lancet and presented at ADA 2026
Retatrutide’s first Phase 3 type 2 diabetes trial, TRANSCEND-T2D-1, was published in The Lancet and presented with TRIUMPH-1 obesity data at ADA 2026.
-
New analytical method improves de novo sequencing of short peptides
Researchers at Kyushu University report a coumarin-tag method in Analytical Chemistry that improves accurate de novo sequencing of short peptides by mass spectrometry.
-
Why a batch-matched Certificate of Analysis still anchors research-peptide quality
As scrutiny of research-peptide quality grows, one principle keeps surfacing: a Certificate of Analysis (COA) is only meaningful when it is tied to the exact batch in hand and reports more than a single purity figure. A useful COA generally documents several things together: identity confirmation (commonly by mass spectrometry), purity (typically by HPLC), and…
-
Study compares semaglutide, tirzepatide, and retatrutide in a genetic obesity mouse model
A peer-reviewed study in the International Journal of Obesity compares three GLP-1–class peptides — semaglutide, tirzepatide, and retatrutide — in a genetic mouse model of obesity. The researchers used MC4R-knockout mice, which lack a receptor central to the brain’s appetite-regulating melanocortin pathway and develop obesity, insulin resistance, and markers of liver stress. Over a 21-day…
-
Retatrutide reports ~28% average weight loss in first Phase 3 obesity trial
Eli Lilly has reported topline results from TRIUMPH-1, the first Phase 3 obesity trial of the triple-agonist peptide retatrutide. Retatrutide acts on three receptors — GLP-1, GIP, and glucagon — distinguishing it from single- and dual-agonist compounds in the same class. According to the company’s announcement, mean body-weight reduction rose with dose: roughly 19% at…
-
PCAC peptide hearing July 23–24: key deadlines arrive this month
Several procedural deadlines for the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides fall within the next few weeks. The committee is scheduled to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, in their free-base and acetate forms — should be eligible for compounding under…
-
FDA comment window on excluding compounded GLP-1s closes June 29
The FDA’s public comment window on whether to keep three popular GLP-1 medicines off the 503B bulk drug substances list closes June 29, 2026. In an April 30, 2026 proposal, the FDA said it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances, given that FDA-approved versions…
-
FDA sets July 23–24 hearing on seven research peptides
The FDA’s Pharmacy Compounding Advisory Committee will review BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon for the 503A compounding bulks list.